cyrilzakka/clinical-trials huggingface dataset:
Effects of Jones Technique and Cross Friction Massage on Cervicogenic Headache.

Cervicogenic headache is a very incessant issue that is often faced by the general population. Cervicogenic headache is a significant issue in patients with upper cervical dysfunction. However, its physical therapy management is a subject of debate. As the Comparative effects of Jones technique and cross-friction massage have never been investigated in patients with cervicogenic headache and neck pain, this study aims to investigate the effects of these treatments on two study groups (Group A\&B) respectively.

This study will be a randomized clinical trial and will be conducted in Al-Khidmat Foundation Sahiwal. The study will be completed within the time duration of six months. A nonprobability convenience sampling technique will be used to collect the data. The sample size of 30 patients will be taken in this study, aged 20-to 50 years, will be allocated to two groups, Group A (Jones technique) and Group B (cross friction massage). Strain counter strain technique also known as the Jones technique will be performed with the patient laid supine on the treatment table, taking them to a position of comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds have elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks.

Group B will get cross friction massage for 15-20 minutes. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively. Assessment will be done via a 6-item Headache Impact scale and neck disability index. The Neck Disability Index will be used to examine neck pain intensity and cervicogenic headache symptoms. The 6-item Headache Impact Test scale will be used to examine headache severity and its adverse effects on social life and functions. A goniometer will be used to assess the rotation range of motion.

Eligibility Criteria:
Inclusion Criteria:

* Headache with neck stiffness and/or pain.
* Headache for the past 3 months at least once per week
* Aged 20-40 years
* Chronic neck pain for more than 3 months
* Baseline NDI score of at least 20% (10 points).
* Forward head posture

Exclusion Criteria

* Headache with neck stiffness and/or pain.
* Headache for the past 3 months at least once per week
* Aged 20-40 years
* Chronic neck pain for more than 3 months
* Baseline NDI score of at least 20% (10 points).
* Forward head posture
Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.

OBJECTIVES: I. Assess the response rate of gemcitabine and cisplatin in the treatment of metastatic breast cancer in patients who have failed one or two systemic regimens. II. Determine time to progression and survival in these patients. III. Define further the toxicity of this two-drug combination in these patients.

OUTLINE: This is a nonrandomized study. Patients receive gemcitabine IV over 30 minutes and cisplatin IV over 1 hour on days 1, 8, and 15 every 28 days. Patients with complete response may receive an additional 2 courses after attainment of complete response status. Treatment continues in the absence of disease progression or unacceptable toxicities for a maximum of 8 courses. Patients are followed every 3 months for 2 years and then at 3 years after treatment.

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologic or cytologic confirmation of metastatic breast cancer with two exceptions: -New or enlarging pulmonary nodules demonstrable on two chest radiographs taken at least one month apart OR -Multiple characteristic lytic bone metastasis or liver metastases Measurable indicator lesion Measurable metastatic disease must be bidimensionally measurable except in the case of hepatomegaly that may be unidimensionally measurable Patients receiving bisphosphonates must have a measurable disease other than bone No CNS metastases unless controlled with prior surgery and/or radiotherapy

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Greater than 3 months Hematopoietic: WBC at least 3500/mm3 or absolute neutrophil count at least 2000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 0.3 mg/dL above upper limit of normal limit (ULN) AST no greater than 3 times ULN Renal: Creatinine no greater than 0.3 mg/dL above ULN Cardiovascular: No New York Heart Association class III or IV heart disease Other: Physician-estimated oral caloric intake of at least 1200 calories per day No uncontrolled infection or chronic debilitating disease Not pregnant or nursing Women of childbearing potential must use adequate contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Must have previously received 1 but no more than 2 chemotherapy regimens At least 1 prior regimen administered for metastatic disease At least 1 prior regimen containing an anthracycline or paclitaxel At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 3 weeks since prior radiotherapy No prior strontium 89 radiotherapy Prior radiotherapy must have been to less than 25% of bone marrow Surgery: At least 4 weeks since any major surgery
Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration, diabetic retinopathy (DR), and glaucoma. The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.

Artificial Intelligence (AI) has shown significant potential in medical imaging analysis and disease diagnosis, particularly in ophthalmology. Substantial advancements have been made in utilizing AI for diagnosing common ophthalmic diseases, enhancing early detection and improving patient outcomes. Early diagnosis of age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma (GLC) is crucial for effective treatment and disease management.

However, current clinical diagnoses rely heavily on ophthalmologists, leading to challenges such as low patient attendance rates and unequal distribution of diagnostic resources. To address these issues, this study adopts a before-and-after trial design to assess the impact of the VeriSee AI-assisted diagnostic system. The study involves both prospective data collection from screenings and retrospective analysis of past patient data.

VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-powered medical software tools designed to screen for AMD, DR, and GLC, respectively. These systems employ advanced AI algorithms to analyze color fundus photography images, assess disease conditions, and evaluate image quality. By integrating this software into clinical workflows, physicians receive instant diagnostic support, improving efficiency and accessibility in ophthalmic disease screening.

Eligibility Criteria:
Inclusion Criteria:

* VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
* VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
* VeriSee GLC is used in non-glaucoma subspecialty ophthalmology clinics for adults aged 20 and above with myopia less than 1000 degrees.

Exclusion Criteria:

* The patient does not agree to participate in the trial or is unable to provide informed consent.
Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance

The aim of this study was to investigate renal function decline by measured glomerular filtration rate (mGFR) in patients with FD during enzyme replacement therapy, and to explore the influence of age on renal function in FD.

Nephropathy is common in Fabry disease (FD). Renal function decline is often the first sign of major organ involvement, sometimes progressing to end-stage renal failure. Available studies of renal function during enzyme replacement therapy have shown inconsistent results, and are based on different composition of patient materials and follow-up time.

Most investigations have used estimated glomerular filtration rate (eGFR) for evaluating renal function. GFR is an important indicator of renal function. eGFR based on a serum creatinine measurement is most commonly used in FD. However, this method has been shown to be unreliable, as serum creatinine levels are influenced by other factors than renal function such as ethnic group, muscle mass, age, hydration and diet. Performance of eGFR in detecting minor changes in renal function is poor. A 10 year old review on renal function evaluation in patients with FD recommended the use of GFR based on an exogenous marker, e.g. Cr-EDTA. Nevertheless, only few studies have used mGFR for evaluation of renal function and to our knowledge, the present study is the first to describe the rate of renal function decline with consecutive mGFR values in a nationwide population of patients with FD.

Renal function declines with age in renal healthy individuals. To our knowledge, the present study is the first to age-standardize renal function in patients with FD to adjust for age-dependent renal deterioration.

Eligibility Criteria:
Inclusion Criteria:

* Genetically and/or enzymatically verified Fabry disease

Exclusion Criteria:

* End-stage renal disease prior to baseline (GFR \<15 ml/min/1.73m2, dialysis or renal transplant)
* Patient has not received enzyme replacement therapy during follow-up
* Patient has had less than 3 measurement of GFR during follow-up
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as type 2 diabetes mellitus;
* Patients who had the intima-media thickness (IMT) of carotid artery ≥1.1 mm in at least one side;
* Patients who had results of aspartate aminotransferase, alanine aminotransferase, and serum creatinine no more than 1.5 times higher than the upper limit of normal;
* Patients who had not cardio or cerebral vascular events within 3 months, including non-fatal myocardial infarction, stable and unstable angina pectoris, and non-fatal cerebral ischemic and hemorrhagic stroke;
* Patients who had their systolic blood pressure \<160 mmHg, diastolic blood pressure \<100 mmHg, and glycated hemoglobin (HbA1c) \<8.0%;
* Patients who had not taken any medications with antithrombotic and antiplatelet effect within 3 months;

Exclusion Criteria:

* Patients who had peptic ulcer or active alimentary tract hemorrhage;
* Patients who had a known allergy to prostacycline or non-steroid medications;
* Patients who were pregnant, breast feeding, or had planned to be pregnant;
* Patients who were attending or had attended any clinical studies within 3 months;
Effects of Blueberries in Older Adults

This randomized, parallel-design trial will evaluate specific clinical and physiological effects of whole blueberries in adults 70 years of age or older.

Although much is already known about the benefits of a healthy diet for the prevention of a wide range of chronic diseases, including the particular health benefits of anthocyanin-rich foods, these effects have been examined with much less frequency in older adults, who tend to be excluded from formal feeding studies and, until recently, have represented a small proportion of ongoing cohort studies. The proposed study will randomize approximately 46 women and 24 men, representative of the proportion of elderly women and men in the U.S. to consume either:

1. 1 cup of frozen blueberries daily for 12 weeks

   or
2. 2-3 dried dates daily for 12 weeks.

Dates were chosen as a control food because they contain negligible polyphenols, proportionately high caloric content, and a convenient form for storage. After the 12-week intervention, researchers will repeat in-person study assessments from baseline.

Eligibility Criteria:
Inclusion Criteria:

* 70 years old
* Independent-living

Exclusion Criteria:

* Cardiovascular event or procedure within 3 months of randomization
* AHA Class III-IV heart failure
* Intolerance or allergy to blueberries or dates
* History of gastric bypass surgery
* Any planned hospitalization or vacation in the ensuing 4 months
* Any current cancer treatment
* End-stage renal disease
* Any organ transplant
* Uncontrolled diabetes mellitus with hemoglobin A1c \>9%
* Systolic blood pressure \>200 mmHg
* Inability to provide personal informed consent (e.g. cognitive impairment)
* Investigator concern
Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD

The objective of this study is to investigate the evidence of dopaminergic toxicity causing by HCV infection using 18F-FDOPA PET and MRS as imaging biomarkers.

Parkinson's disease (PD) is the most common neurodegenerative disorder after Alzheimer's disease. It is characterized by degeneration of the dopaminergic neurons in substantia nigra and striatum, even before the clinical symptoms develop. Although the pathogenesis is still unclear, some viruses have been shown to be associated with acute or chronic parkinsonism. Recent studies have found that Hepatitis C virus (HCV) can replicate in the central nervous system, suggesting a possible link between PD and HCV. At the population and epidemiology level, the HCV infection and PD are strongly associated. At the molecular level, both HCV and PD have in common the overexpression of inflammatory biomarkers. Neuronal toxicity induced by HCV was also demonstrated. The positive association between HCV infection and PD has clinical implications for high endemic HCV areas, including Taiwan.

18F-FDOPA, an analog to L-DOPA, has been used as a positron-emitting compound for PET examination of patients affected by PD. It has been shown that putamen 18F-FDOPA uptakes are reduced by at least 35% at onset of symptoms, making the 18F-FDOPA PET as an imaging biomarker for detecting subclinical and preclinical parkinsonism. Earlier imaging study using magnetic resonance spectroscopy (MRS) to investigate cerebral effect of HCV also showed that chronic HCV infection had elevated choline/creatine ratios, a biomarker indicating inflammatory and infective conditions, in the basal ganglia and white matter.

The objective of this study is to investigate the evidence of dopaminergic toxicity causing by HCV infection using 18F-FDOPA PET and MRS as imaging biomarkers.

Eligibility Criteria:
Inclusion Criteria:

* Test Group

  1. Age：above 20 years old with HBV or HCV subjects.
  2. Patient agrees to participate in the study and receive UPDRS, MMSE, BDI II, MRI and PET imaging.
* Control Group

  1. Age：above 20 years old without carriers of Hepatitis B and C (ex. fatty liver), and no known neurological (ex. stroke, Parkinson's disease and degenerative neuropathy, etc.) and mental illness.
  2. Patient agrees to participate in the study and receive UPDRS, MMSE, BDI II, MRI and PET imaging.

Exclusion Criteria:

1. Patients could not receive PET and MRI studies, including panic mood to MRI study, allergy to contrast medium, hemodynamic instability.
2. Patients with pregnancy or recently having a plan for pregnancy.
3. Patient or family who does not agree to participate in the study
Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer

Treatment of rectal cancer often consists of surgical resection of the tumor. Chemotherapy and/or radiotherapy are frequently given before or after surgery. In this study, we wish to learn if there are differences in the treatment effectiveness or in the quality of life of patients based on their type of treatment (e.g. Radiotherapy and chemotherapy before or after surgery). Information from this questionnaire collected from you and other patients may help improve the quality of life of rectal cancer patients in the future. Medical information on your tumor, treatment received, and side effects will be compiled and maintained in a database to learn more about outcomes of treatment for rectal cancer.

There exists little published data studying the health related quality of life (HRQOL) of patients treated for the rectal cancer. Patients are commonly treated with surgery preceded or followed by chemo radiotherapy. Patients chart review and questionnaires administered during follow-up exam or by mailing will be use to compile data comparing the HRQOL of the two study groups(Preoperative versus Post operative chemotherapy).

Our Radiation Oncologist will also informed all the new pts. under going radiotherapy regarding this study and will encourage them in become part of our study population. The prospective study will help us in increasing the number of participants and also it give us an opportunity following the patients as they go through their treatment.

Through the use of department databases, a cohort or rectal cancer patients treated at Stanford will be identified. Patients demographics, treatment received ,disease outcomes, and treatment associated complications will be compiled from available data. HRQOL questionnaires will be answered through a mailing or during clinic visits. Treatment outcomes, toxicities and overall quality of life of preoperative and postoperative chemo radiotherapy treatment group will be compared in relation to the lesion location.

Eligibility Criteria:
Inclusion Criteria:History of histologically-confirmed rectal cancer with treatment or undergoing treatment at Stanford University Hospital.
Investigation of the Effects of Classical Massage Application on Individuals With Chronic Low Back Pain

The aim of this study is to examine the effects of classical massage on pain, spinal mobility, functional and psychological state, and life quality in individuals with chronic low back pain.

Low back pain is one of the most common problems in society, experienced by 70-80% of individuals at least once in their lifetime. Physical pain can cause serious functional losses that affect independence in daily life. In patients with low back pain, physical endurance decreases because of pain, spasm, decrease in muscle strength and deteriorated posture, and the functional capacity and quality of life of the patient are negatively affected. While most individuals recover spontaneously, 2-8% of them require medical treatment, and the response to conservative treatment is generally good. Along with medical treatment, different physiotherapy methods (electro-physical agents, massage, traction, exercises, etc.), which are conservative treatment methods, are also frequently used. It is known that classical physiotherapy modalities (heating agents and exercise approaches) have an important place in the treatment of these patients due to their positive effects on pain, strength, flexibility and functionality. Massage is used to systematically manipulate the soft tissues of the body with rhythmic pressure and to provide or maintain health. Basically, massage is a simple way to provide pain relief through physical and mental relaxation. It is thought to relieve pain in various ways, including increasing the pain threshold by secreting endorphins and closing the pain gate at the spinal cord level. Classical massage is considered rehabilitative and is also used to reduce symptoms associated with medical conditions. It has been reported that classical massage reduces many physical and psychological symptoms in different musculoskeletal problems (neck pain, fibromyalgia, etc.). However, there is a need for placebo-controlled studies in the literature examining the effects of classical massage in individuals with chronic low back pain.

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18-65,
* Having non-specific low back pain lasting at least 3 months,
* Individuals willing to participate in the study

Exclusion Criteria:

* Having different pain syndromes (eg fibromyalgia)
* Having a history of spinal surgery or invasive examination in the last 6 months,
* Having a neurological or psychiatric disease
* Any ongoing related pathology (eg spondylolisthesis, fractures, tumor, osteoporosis or infection),
* Those with pregnancy status
The Role of Splinting in Fingertip Injuries

This study is attempting to understand whether or not splinting after a fingertip injury improves recovery.


Eligibility Criteria:
Inclusion Criteria:

* injury distal to flexor and extensor tendon insertions
* crush, avulsion, amputation, or penetrating injury to the fingertip
* isolated injury, within two weeks

Exclusion Criteria:

* operative fixation required
* unable to participate in rehab
Perioperative Risk Calculator

The aim of this project is to develop a machine-learning model for calculating the risk of postoperative complications. In addition to the data collected during the premedication, the model will include all intraoperative values recorded in the Patient Data Management System (PDMS), which include not only vital and respiratory parameters, but also medication and doses, intraoperative events and times. Postoperative complications are defined according to their severity according to the Clavien-Dindo score (Dindo, Demartines et al., 2004) and are collected from the data available in the health information system (HIS).

The machine-learning model is created using an extreme-gradient boosting algorithm which has been updated with new data from the year 2021 to ensure accuracy of the model.


Eligibility Criteria:
Inclusion Criteria:

* all patients who underwent surgery with anesthesia

Exclusion Criteria:

* none